drugset / Trial / NCT00125320
Response to RSD1235 Compared to Placebo in Subjects With Atrial Arrhythmia After Heart Surgery
Phase 3
Completed
190 enrolled
Astellas Pharma Inc
Advanz Pharma · collabAstellas Pharma US, Inc. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to demonstrate the safety and efficacy of RSD1235 compared to placebo in the conversion of atrial arrhythmia to sinus rhythm in subjects following valvular and/or coronary artery bypass graft surgery.
Timeline
- Start
- 2004-06
- Primary completion
- 2007-02
- Completion
- 2007-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vernakalant | Other / unclassified | 3 mg/kg | Intravenous |